Selecting a contract development and manufacturing organization (CDMO) is a critical decision for pharmaceutical companies. The right partner can streamline the drug development process, ensure regulatory compliance, and mitigate risks. The wrong choice can lead to delays, increased costs, and quality issues. Companies must assess their specific needs and evaluate potential CDMOs based on expertise, technical capabilities, regulatory experience, and risk management. In this blog, we’ll explore the essential considerations when choosing a CDMO.

Key Factors to Consider When Choosing a CDMO

1. Understanding Your Development and Manufacturing Needs

Before selecting a CDMO, a company must determine the stage of development and the type of support required. Some organizations need both development and manufacturing, while others may only require one. A CDMO should have expertise in the specific molecule or drug product type—small molecules, biologics, cell and gene therapy, oral or sterile injectables. A strong track record in developing and manufacturing similar products is essential.

2. Expertise and Regulatory History

Navigating regulatory requirements is one of the most challenging aspects of drug development. Companies should consider where they intend to submit their drug applications and ensure the CDMO has experience with the relevant regulatory authorities, such as the FDA, EMA, or PMDA. Each market has unique compliance standards, and a CDMO with a strong history of successful submissions can prevent regulatory setbacks.

Case Study: A biotech firm seeking FDA approval faced challenges with their original CDMO, which lacked experience in U.S. regulatory pathways. Upon switching to Olon USA, they achieved compliance and accelerated their approval timeline.

3. Technical Capabilities and Facility Assessment

A thorough assessment of a CDMO’s technical expertise and infrastructure is necessary. Site visits allow companies to evaluate facilities, equipment, and analytical instrumentation. Meeting the scientific team provides insight into their problem-solving approach and communication style. A seamless collaboration between internal teams and the CDMO’s scientists improves development efficiency and helps navigate potential challenges.

Checklist for Facility Evaluation:

• Does the CDMO have state-of-the-art equipment for your specific drug type?
• Are their quality control and quality assurance teams well-established?
• Do they offer scalability from clinical trials to commercial production?

4. Risk Management Beyond Cost Considerations

Cost is an important factor, but focusing solely on the lowest bid can lead to significant risks. Lower-cost CDMOs may lack scalability, leading to unexpected delays and additional expenses. Offshore CDMOs can present logistical challenges, including travel restrictions that may hinder oversight and troubleshooting. A CDMO should be selected based on a balance of cost, risk mitigation, and long-term project success.

Key Risk Considerations:

• Supply chain resilience: Can they handle disruptions in raw material supply?
• Regulatory compliance: Do they have a strong compliance history with the appropriate regulatory agencies?
• Geographic factors: Will time zone differences and international regulations create bottlenecks or communication issues?

5. Avoiding Common Pitfalls

Companies frequently encounter issues when they choose a CDMO that overpromises and underdelivers. Insufficient technical expertise, delays, and regulatory non-compliance can derail a program. Olon USA has stepped in on multiple occasions to rescue programs from CDMOs that failed to meet expectations. A CDMO should be evaluated not just on price but on its ability to deliver quality results efficiently.

6. Choosing a Reliable Partner

A CDMO should function as an extension of the client’s team, providing technical expertise, regulatory insight, and reliable manufacturing processes. A strong working relationship ensures that challenges can be addressed quickly, and project timelines remain intact. Companies that invest the time to thoroughly vet potential CDMO partners increase the likelihood of a successful outcome.

Partnering with Olon USA

Olon USA, a subsidiary of the Olon Group, is a trusted name in contract research, development, and manufacturing. Established in 1986 and acquired by Olon SpA in 2017, the company specializes in offering services from preclinical active pharmaceutical ingredient (API) development to commercial manufacturing. With 160,000 square feet of laboratory and manufacturing space, Olon USA provides end-to-end solutions tailored to pharmaceutical development.

Why Choose Olon USA?

• Proven Regulatory Expertise: Extensive experience in FDA submissions and compliance.
• Robust Infrastructure: Advanced laboratories and manufacturing capabilities.
• Strong Risk Management: Strategic approach to mitigate supply chain disruptions and quality issues.
• Rescue Project Experience: Successfully reviving troubled programs from underperforming CDMOs.

Take the Next Step

Choosing a CDMO is more than a transaction—it is a strategic partnership. Olon USA combines technical expertise, regulatory excellence, and a commitment to project success.

Want to ensure your project stays on track? Schedule a consultation with Olon USA today to explore how a strong partnership can drive development forward.